ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

MXCT MaxCyte Inc

3,77
-0,06 (-1,57%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
MaxCyte Inc MXCT NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,06 -1,57% 3,77 00:30:10
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,95 3,74 3,95 3,77 3,83
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
10.4.202414:05GLOBEMaxCyte to Report First Quarter 2024 Financial Results on..
02.4.202414:05GLOBEMaxCyte Signs Strategic Platform License with Be Biopharma..
12.3.202421:05GLOBEMaxCyte Reports Fourth Quarter and Full Year 2023 Financial..
05.3.202422:15EDGAR2Form 8-K - Current report
04.3.202423:39EDGAR2Form 3 - Initial statement of beneficial ownership of..
04.3.202422:05GLOBEMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023..
26.2.202422:22EDGAR2Form 144 - Report of proposed sale of securities
14.2.202422:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202418:25EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09.2.202414:05GLOBEMaxCyte to Report Fourth Quarter and Full Year 2023..
01.2.202422:25EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30.1.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.1.202414:05GLOBEMaxCyte and Wugen Sign Strategic Platform License to..
26.1.202422:45EDGAR2Form 8-K - Current report
26.1.202417:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23.1.202414:05GLOBEMaxCyte Signs Strategic Platform License with Imugene to..
08.1.202422:15EDGAR2Form 8-K - Current report
08.1.202422:05GLOBEMaxCyte Announces Preliminary Unaudited Fourth Quarter and..
04.1.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202414:05GLOBEMaxCyte and Lion TCR form Partnership to Support Global..
02.1.202408:00GLOBEMaxCyte Confirms Appointment of Maher Masoud as President,..
28.12.202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.12.202322:30EDGAR2Form 8-K - Current report
11.12.202322:05GLOBEMaxCyte Announces CEO Transition and Updates Revenue..
06.12.202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.12.202323:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.11.202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.11.202322:32EDGAR2Form 144 - Report of proposed sale of securities
17.11.202322:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16.11.202322:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.11.202314:05GLOBEMaxCyte Joins the Alliance for mRNA Medicines (AMM) as a..
08.11.202323:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.11.202322:12EDGAR2Form 8-K - Current report
08.11.202322:05GLOBEMaxCyte Reports Third Quarter 2023 Financial Results and..
06.11.202322:05GLOBEMaxCyte to Participate in Two Upcoming Investor Conferences
04.10.202322:14EDGAR2Form 8-K - Current report
04.10.202322:05GLOBEMaxCyte Announces Preliminary Third Quarter 2023 Revenue and..
06.9.202314:05GLOBEMaxCyte Appoints Ali Soleymannezhad as Executive Vice..
05.9.202314:05GLOBEMaxCyte to Participate in Baird Global Healthcare Conference
30.8.202323:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.8.202322:55EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.8.202322:16EDGAR2Form 8-K - Current report
09.8.202322:05GLOBEMaxCyte Reports Second Quarter and Half-Year 2023 Financial..
01.8.202314:05GLOBEMaxCyte Signs Strategic Platform License with Prime Medicine..
28.7.202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.7.202314:05GLOBEMaxCyte to Report Second Quarter 2023 Financial Results on..
13.7.202300:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.7.202322:51EDGAR2Form 144 - Report of proposed sale of securities
10.7.202314:05GLOBEMaxCyte and Vittoria Biotherapeutics Sign Strategic Platform..
06.7.202314:05GLOBEMaxCyte Signs Strategic Platform License with Lyell..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock